Lartruvo OverviewOlaratumab is a monoclonal antibody which is being developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft tissue sarcoma. In October 2016, the FDA issued an approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS). Referen...
Read more Lartruvo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaratumab
Recent Lartruvo Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 500mg/50ml, 500mg/50ml(10mg/ml)
NDC Database Records for Lartruvo: (1 result)Sorted by National Drug Code
- 0002-8926 Lartruvo 10 mg/ml Intravenous Solution by Eli Lilly and Company